TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000296370
  • Gene Name:S100P
  • mRNA database:Ensembl
  • mRNA expression :up-regulated
  • mRNA Method:Northern blot
  • mRNA Pathway:NA
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB00515 (APRD00359)
  • Drug Name:Cisplatin
  • Drug Method:up-regulated the gene expression

Disease basic infommation

  • Disease:bladder cancer
  • Tissue:cell lines (T24, KK47,T24/DDP10, KK47/DDP20)

Other information

  • Title:Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin
  • Journal:BJU Int
  • Published:2011
  • PubMed ID:20726978
  • Abstract:Objective:? To investigate the role of S100 calcium-binding protein P (S100P) in the gain of cis-diamminedichloroplatinum (II) (cisplatin) resistance in bladder cancer, having previously found, with cDNA microarrays using two pairs of parental (T24, KK47) and their cisplatin-resistant bladder cancer cell lines (T24/DDP10, KK47/DDP20), that S100P mRNA expression was significantly reduced in cisplatin-resistant cells. Materials and methods:? S100P mRNA and protein expression levels were investigated by northern and western blot analyses, respectively. ? Intracellular S100P localization was examined by immunocytochemistry and immunohistochemistry. ? S100P over-expression, obtained by transfection with S100P expression plasmid, was used to investigate whether or not S100P affected cellular resistance to cisplatin. Results:? S100P mRNA showed increased expression by cisplatin stimulation in parental cell lines. ? On the other hand, S100P mRNA and protein expression levels were markedly reduced in cisplatin-resistant cells. ? The over-expression of S100P in resistant cells resulted in an increased sensitivity to cisplatin. Conclusions:? In bladder cancer cells, S100P was expressed and localized mainly in the nucleus. ? S100P expression was also involved in cisplatin sensitivity. ? S100P might thus represent a molecular marker predicting cisplatin sensitivity and a molecular therapeutic target for cisplatin-based chemotherapy.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3